R
34.60
0.98 (2.91%)
| Previous Close | 33.62 |
| Open | 33.28 |
| Volume | 3,707,281 |
| Avg. Volume (3M) | 1,354,605 |
| Market Cap | 6,432,589,312 |
| Price / Sales | 9.04 |
| Price / Book | 2.76 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -3.58 |
| Total Debt/Equity (MRQ) | 6.00% |
| Current Ratio (MRQ) | 14.20 |
| Operating Cash Flow (TTM) | -557.44 M |
| Levered Free Cash Flow (TTM) | -347.69 M |
| Return on Assets (TTM) | -18.66% |
| Return on Equity (TTM) | -29.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Revolution Medicines, Inc. | Bearish | Bullish |
AIStockmoo Score
0.6
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | 4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.60 |
|
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.05% |
| % Held by Institutions | 106.33% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nextech Invest Ltd. | 31 Dec 2024 | 7,601,087 |
| Bellevue Group Ag | 31 Dec 2024 | 4,386,900 |
| Boxer Capital, Llc | 30 Sep 2024 | 4,279,464 |
| Boxer Capital Management, Llc | 31 Dec 2024 | 4,279,464 |
| Bvf Inc/Il | 31 Dec 2024 | 4,181,179 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 73.00 (HC Wainwright & Co., 110.98%) | Buy |
| Median | 67.50 (95.09%) | |
| Low | 59.00 (Needham, 70.52%) | Buy |
| Average | 66.75 (92.92%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 38.87 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 01 Apr 2025 | 64.00 (84.97%) | Buy | 33.62 |
| 27 Feb 2025 | 78.00 (125.43%) | Buy | 39.08 | |
| HC Wainwright & Co. | 03 Mar 2025 | 73.00 (110.98%) | Buy | 38.34 |
| Needham | 27 Feb 2025 | 59.00 (70.52%) | Buy | 39.08 |
| UBS | 08 Jan 2025 | 71.00 (105.20%) | Buy | 44.42 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Apr 2025 | Announcement | Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting |
| 31 Mar 2025 | Announcement | Revolution Medicines to Participate in April 2025 Investor Conferences |
| 26 Feb 2025 | Announcement | Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress |
| 24 Feb 2025 | Announcement | Revolution Medicines to Participate in March 2025 Investor Conferences |
| 19 Feb 2025 | Announcement | Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 |
| 29 Jan 2025 | Announcement | Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference |
| 06 Jan 2025 | Announcement | Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |